Archives

by in
Entry Author Date Location
Why It’s Time to Retire the Term “Life Sciences” 03/04/14 Seattle
San Diego Life Sciences Roundup: Thesan, Zogenix, Illumina, and More 02/28/14 San Diego
Drug Development 101: A Story About OncoGenex and the FDA 02/26/14 Seattle
San Diego Life Sciences Roundup: Lithera, CardioCell, and More 02/21/14 San Diego
Molecular Diagnostics Are in a Rut. The Industry Needs the FDA 02/17/14 National
East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More 02/14/14 Boston
Pharmacyclics, J&J Get FDA Nod for Chronic Lymphocytic Leukemia Drug 02/12/14 San Francisco
Austin’s Lumos Pharma Gets $14M for Creatine Disorder Therapy 02/07/14 Texas
Houston’s OrthoAccel Mouthpiece Can Make Braces Work Faster 01/30/14 Texas
Lucigen Takes On Diagnostic Giants With On-the-Spot Pathogen Tests 01/30/14 Wisconsin
Texas Biotech Leaders Doubt CPRIT Will Get Its Groove Back 01/24/14 Texas
East Coast Biotech Roundup: Enanta, NY Disruptors, Repligen, & More 01/24/14 Boston
Social Media & Cancer Drugs: Conversation, not Promotion 01/23/14 Wisconsin
Promentis’s $2.9M Series B Round to Fund Human Trials 01/16/14 Wisconsin
San Diego Life Sciences Roundup: Receptos, Auspex, Avelas, and More 01/10/14 San Diego
Ariad’s Cancer Drug to Return to U.S. in January, Shares Soar 12/20/13 Boston
How WARF Plans to Stay Relevant in Lean Times for Tech Transfer 12/20/13 Wisconsin
Houston’s Decisio Crunches Patient Data for Better Care 12/18/13 Texas
Exact Sciences, Once Near Death, Bounces Back With Colon Cancer Test 12/18/13 Wisconsin
What Was Hyped, and What Fell Out of Favor, This Year in Biotech 12/16/13 National
San Diego Life Sciences Roundup: Orexigen, Accelrys, Otonomy, & More 12/13/13 San Diego
There May Be More to the FDA/23andMe Story Than Meets the Eye 12/12/13 Boston
Savient Pharma Sells to GTCR-Backed Crealta For $120M 12/11/13 New York
12 Things the Pharma Industry Can Do to Rebuild Real Public Trust 12/09/13 National
San Diego Life Sciences Roundup: Ignyta, Conatus, Liver Prize & More 12/06/13 San Diego
FDA’s Culture Is Genetically Dominant Over 23andMe’s Business Model 12/05/13 National
San Diego Life Sciences Roundup: Orexigen, Avalon, GSK, and More 11/27/13 San Diego
23andMe: Victim of an Overboard FDA Crackdown, or Provocateur? 11/26/13 Seattle
East Coast Biotech Roundup: Sarepta, Zalicus, Alkermes, & More 11/15/13 Boston
Sarepta Shares Crumble As FDA Calls New Drug Application “Premature” 11/12/13 Boston
Page 3 of 40 « previous page · next page »